En vivo
Endpoints NewsRA, Forbion and Sanofi Ventures appear to back new eye drug from KoreaEndpoints NewsNovocure’s electric fields therapy fails key glioblastoma studyPharmaVoiceAs M&A rebounds, here’s how pharmas can prepare to seal a dealFierceBiotechKardigan buttons up $400M upsized IPO to power heart drugs toward phase 3FierceBiotechNovocure device fails to improve brain cancer patients’ survival in phase 3 testFierceBiotechNortiva purrs into action with long-acting Lynx platform salvaged from Langer startupEndpoints NewsInnoviva revives Lyndra's long-acting oral drug platformFierceBiotechBiogen inks $1B RayThera buyout to bag preclinical immunology assetsEndpoints NewsModerna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departsEndpoints NewsEli Lilly's TuneLab hits 100 members, adding Chai's AI modelsCellChloroplast sunscreening by protein condensates confers high-light tolerancePharmaVoiceA new Westlake-backed biotech takes aim at migraines
Este artículo no está disponible en el archivo.